LARGER VIALS = LARGER SAVINGS PER mg

FOXO4-DRI

FOXO4-DRI

$148.00
$148.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

FOXO4-DRI

FOXO4-DRI

$148.00
$148.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

FOXO4-DRI is a synthetic peptide designed to interfere with the interaction between the transcription factor FOXO4 and p53. By disrupting this binding, it promotes apoptosis of senescent cells, a process studied for its potential role in healthy aging and age-related disease management.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

FOXO4-DRI (FOXO4 D-retro inverso peptide) is a synthetic peptide designed to disrupt the interaction between the transcription factor FOXO4 and the tumor suppressor protein p53. This selective disruption triggers apoptosis in senescent cells while sparing normal, healthy cells. By clearing senescent cells (senolysis), FOXO4-DRI has been studied as a potential therapeutic candidate for aging, tissue degeneration, and age-related diseases.

Structure

  • Type: Synthetic D-retro inverso peptide
  • Sequence: Modified FOXO4 motif that binds p53 (reversed and D-amino acid substituted for stability)
  • Molecular Weight: ~5–6 kDa (depending on preparation)
  • Mechanism: Blocks FOXO4–p53 binding → induces apoptosis selectively in senescent cells

Research

Cellular Senescence & Aging

  • Senescent cells accumulate with age and contribute to chronic inflammation (“inflammaging”), tissue dysfunction, and age-related decline.

  • FOXO4-DRI forces senescent cells into apoptosis, rejuvenating tissues by removing pro-inflammatory senescent cells.

Tissue Regeneration

In preclinical studies, FOXO4-DRI has been shown to:

  • Improve kidney function in mouse models of renal injury
  • Enhance fur density and physical activity in aged mice
  • Reverse age-related muscle wasting

Neurodegeneration

Experimental evidence suggests FOXO4-DRI may protect against neurodegeneration by reducing senescent cell burden in the brain, potentially relevant for Parkinson’s disease and Alzheimer’s disease models.

Cancer Research

By modulating the FOXO4–p53 interaction, FOXO4-DRI has been proposed as a senolytic adjuvant in cancer therapy, possibly reducing tumor microenvironment senescence that contributes to resistance and relapse.

Safety Profile

Preclinical animal data suggest FOXO4-DRI is well tolerated at research doses. However, human clinical safety data are not yet available, and more studies are needed before translational applications.

Summary

FOXO4-DRI is a senolytic peptide that eliminates senescent cells by blocking FOXO4–p53 binding. Research highlights include:

  • Clearance of senescent cells in multiple tissues
  • Improvement of organ function and vitality in aging models
  • Potential application in aging, tissue regeneration, and neurodegeneration
  • Considered one of the most promising senolytic compounds in experimental geroscience

This peptide is supplied as a lyophilized powder. Store vials at 2–8 °C, protected from light and moisture. For long-term storage, keep unopened vials at −20 °C. After reconstitution, prepare solutions under sterile conditions, refrigerate at 2–8 °C, and use promptly. Avoid repeated freeze–thaw cycles.

1. Baar MP, et al. Targeted apoptosis of senescent cells restores tissue homeostasis. Cell. 2017;169(1):132–147.e16. doi:10.1016/j.cell.2017.02.031

2. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease. Nat Med. 2015;21(12):1424–1435. doi:10.1038/nm.4000

3. Baker DJ, et al. Clearance of p16Ink4a-positive senescent cells delays aging-associated disorders. Nature. 2011;479(7372):232–236. doi:10.1038/nature10600

4. Zhu Y, et al. The Achilles’ heel of senescent cells: senolytic targets and approaches. Nat Med. 2015;21(6):666–677. doi:10.1038/nm.3885

5. Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine. 2017;21:21–28. doi:10.1016/j.ebiom.2017.04.013

6. Xu M, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246–1256. doi:10.1038/s41591-018-0092-9

7. Yosef R, et al. Directed elimination of senescent cells by inhibition of anti-apoptotic pathways. Nat Commun. 2016;7:11190. doi:10.1038/ncomms11190

8. Herranz N, Gil J. Mechanisms and functions of cellular senescence. J Clin Invest. 2018;128(4):1238–1246. doi:10.1172/JCI95148

9. Di Micco R, Krizhanovsky V, Baker D, d’Adda di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol. 2021;22(2):75–95. doi:10.1038/s41580-020-00314-w

10. Schafer MJ, et al. Cellular senescence and the senescence-associated secretory phenotype: therapeutic opportunities. J Clin Invest. 2020;130(12):5693–5706. doi:10.1172/JCI137472